|Comparison of EndoPredict and EPclin with oncotype DX recurrence score for prediction of risk of distant recurrence after endocrine therapy|
R Buus, I Sestak, R Kronenwett, C Denkert, P Dubsky, K Krappmann, ...
Journal of the National Cancer Institute 108 (11), djw149, 2016
|Comparison of the performance of 6 prognostic signatures for estrogen receptor–positive breast cancer: a secondary analysis of a randomized clinical trial|
I Sestak, R Buus, J Cuzick, P Dubsky, R Kronenwett, C Denkert, S Ferree, ...
JAMA oncology 4 (4), 545-553, 2018
|PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer|
F Brasó-Maristany, S Filosto, S Catchpole, R Marlow, J Quist, ...
Nature medicine 22 (11), 1303-1313, 2016
|Key role of phosphoinositide 3-kinase class IB in pancreatic cancer|
CE Edling, F Selvaggi, R Buus, T Maffucci, P Di Sebastiano, H Friess, ...
Clinical cancer research 16 (20), 4928-4937, 2010
|Deubiquitinase activities required for hepatocyte growth factor-induced scattering of epithelial cells|
R Buus, M Faronato, DE Hammond, S Urbé, MJ Clague
Current Biology 19 (17), 1463-1466, 2009
|Targeting phosphoinositide 3-kinase pathways in pancreatic cancer-from molecular signalling to clinical trials|
M Falasca, F Selvaggi, R Buus, S Sulpizio, C E Edling
Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal …, 2011
|Regulation of ErbB2 receptor status by the proteasomal DUB POH1|
H Liu, R Buus, MJ Clague, S Urbé
PloS one 4 (5), e5544, 2009
|Changes in expression of genes representing key biologic processes after neoadjuvant chemotherapy in breast cancer, and prognostic implications in residual disease|
M Klintman, R Buus, MCU Cheang, A Sheri, IE Smith, M Dowsett
Clinical cancer research 22 (10), 2405-2416, 2016
|Estrogen receptor expression in 21-gene recurrence score predicts increased late recurrence for estrogen-positive/HER2-negative breast cancer|
M Dowsett, I Sestak, R Buus, E Lopez-Knowles, E Mallon, A Howell, ...
Clinical Cancer Research 21 (12), 2763-2770, 2015
|Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone|
I Sestak, M Martín, P Dubsky, R Kronenwett, F Rojo, J Cuzick, M Filipits, ...
Breast cancer research and treatment 176 (2), 377-386, 2019
|Abstract S6-05: Comprehensive comparison of prognostic signatures for breast cancer in TransATAC|
I Sestak, R Buus, J Cuzick, P Dubsky, R Kronenwett, S Ferree, D Sgroi, ...
Cancer Research 77 (4 Supplement), S6-05-S6-05, 2017
|Class II phosphoinositide 3-kinase C2β regulates a novel signaling pathway involved in breast cancer progression|
A Chikh, R Ferro, JJ Abbott, R Pińeiro, R Buus, M Iezzi, F Ricci, ...
Oncotarget 7 (14), 18325, 2016
|Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations|
E Lopez-Knowles, A Pearson, G Schuster, P Gellert, R Ribas, B Yeo, ...
British journal of cancer 120 (2), 247-255, 2019
|Comprehensive comparison of prognostic signatures for breast cancer recurrence in TransATAC|
I Sestak, R Buus, J Cuzick, P Dudsky, R Kronenwett, S Ferree, D Sgroi, ...
San Antonio Breast Cancer Symposium, S6-S05, 2016
|Genetic and epigenetic regulation of phosphoinositide 3-kinase isoforms|
C Fyffe, R Buus, M Falasca
Current pharmaceutical design 19 (4), 680-686, 2013
|Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer|
R Buus, B Yeo, AR Brentnall, M Klintman, MCU Cheang, K Khabra, ...
Breast Cancer Research 20 (1), 103, 2018
|Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors|
MF Leal, BP Haynes, E Schuster, B Yeo, M Afentakis, L Zabaglo, ...
Clinical Cancer Research 25 (24), 7485-7496, 2019
|Menstrual cycle associated changes in hormone-related gene expression in oestrogen receptor positive breast cancer|
BP Haynes, O Ginsburg, Q Gao, E Folkerd, M Afentakis, R Buus, PT Han, ...
NPJ breast cancer 5 (1), 1-11, 2019
|Gene expression modules in primary breast cancers as risk factors for organotropic patterns of first metastatic spread: a case control study|
K Lawler, E Papouli, C Naceur-Lombardelli, A Mera, K Ougham, A Tutt, ...
Breast Cancer Research 19 (1), 113, 2017
|Erratum: PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.|
F Braso-Maristany, S Filosto, S Catchpole, R Marlow, J Quist, ...
Nature medicine 23 (4), 526, 2017